Investigação desconfia de métodos discutíveis para forçar a subida de preços:
http://www.dailymail.co.uk/news/article-4411194/Drug-giant-plotted-destroy-stocks-cancer-medicines.html
http://www.dailymail.co.uk/news/article-4411194/Drug-giant-plotted-destroy-stocks-cancer-medicines.html
Citando:
"The paper reported that in 2013 the cost of leukaemia drug busulfan rose from £5.20 to £65.22 in England and Wales, a 1,100 per cent jump, while blood cancer medicine chlorambucil went from £8.36 per pack to £40.51.
"The paper reported that in 2013 the cost of leukaemia drug busulfan rose from £5.20 to £65.22 in England and Wales, a 1,100 per cent jump, while blood cancer medicine chlorambucil went from £8.36 per pack to £40.51.
It is understood Aspen was able to impose the price rises by taking advantage of a loophole that allows increases if a brand name is dropped."
